| abstract |
(57) [Summary] [PROBLEMS] To suppress the expression of an endoplasmic reticulum chaperone and to enhance the expression of an endoplasmic reticulum chaperone or to secrete a newly secreted protein or a membrane protein, which are closely associated with the development of cancer, arteriosclerosis or cystic fibrosis. To provide a therapeutic or prophylactic agent for the above-mentioned diseases accompanied by deficiency. An ER chaperone gene expression inhibitor comprising an ATP-sensitive potassium channel opener, and a therapeutic or prophylactic agent for a disease associated with enhanced ER chaperone gene expression, comprising the expression inhibitor as an active ingredient. And a therapeutic or prophylactic agent for a disease associated with deficiency in secretion of a newly secreted protein or a membrane protein, which comprises the expression inhibitor as an active ingredient. |